A detailed history of D. E. Shaw & Co., Inc. transactions in Hutchmed (China) LTD stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 99,538 shares of HCM stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,538
Previous 140,473 29.14%
Holding current value
$1.79 Million
Previous $2.36 Million 27.77%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$16.36 - $21.78 $669,696 - $891,564
-40,935 Reduced 29.14%
99,538 $1.7 Million
Q1 2024

May 15, 2024

SELL
$12.08 - $18.56 $279,446 - $429,348
-23,133 Reduced 14.14%
140,473 $2.36 Million
Q4 2023

Feb 14, 2024

BUY
$16.25 - $20.23 $561,518 - $699,047
34,555 Added 26.78%
163,606 $2.96 Million
Q3 2023

Nov 14, 2023

BUY
$11.85 - $16.95 $2,287 - $3,271
193 Added 0.15%
129,051 $2.19 Million
Q2 2023

Aug 14, 2023

SELL
$10.78 - $17.73 $174,646 - $287,243
-16,201 Reduced 11.17%
128,858 $1.55 Million
Q1 2023

May 15, 2023

SELL
$13.02 - $19.87 $1.25 Million - $1.9 Million
-95,797 Reduced 39.77%
145,059 $1.89 Million
Q4 2022

Feb 14, 2023

BUY
$7.65 - $15.51 $1.84 Million - $3.74 Million
240,856 New
240,856 $3.56 Million
Q4 2021

Feb 14, 2022

SELL
$28.89 - $35.33 $934,995 - $1.14 Million
-32,364 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $898,703 - $1.08 Million
25,202 Added 351.88%
32,364 $1.19 Million
Q2 2021

Aug 16, 2021

SELL
$23.7 - $39.27 $459,969 - $762,152
-19,408 Reduced 73.04%
7,162 $281,000
Q1 2021

May 17, 2021

SELL
$27.01 - $36.8 $158,467 - $215,905
-5,867 Reduced 18.09%
26,570 $751,000
Q4 2020

Feb 16, 2021

BUY
$27.51 - $34.36 $892,341 - $1.11 Million
32,437 New
32,437 $1.04 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.